Top View
- 2018 ASCO Annual Meeting J Clin Oncol 36, 2018 (Suppl; Abstr
- The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications
- Erbb 3 (ERBB3) Human Shrna Plasmid Kit (Locus ID 2065) Product Data
- ERBB/Epidermal Growth Factor Receptor Family: Evidence
- Breast Cancer Expressing the Activated HER2/Neu Is Sensitive to Gefitinib in Vitro and in Vivo and Acquires Resistance Through a Novelpoint Mutation in the HER2/Neu
- Effects of Localized Ephb2 Stimulation on Dendritic Filopodia of Hippocampal Neurons Clifford Locke University of Connecticut - Storrs, [email protected]
- Targeting the Dimerization of ERBB Receptor Tyrosine Kinases Rob Yang Washington University in St
- Heparan Sulfate Regulates Ephrin-A3/Epha Receptor Signaling
- A Conditional Feedback Loop Regulates Ras Activity Through Epha2
- Erbb Signaling Interrupted: Targeting Ligand-Induced Pathway Activation Frederick H
- Coactivated Platelet-Derived Growth Factor Receptor Α and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma
- Latency, Gene Expression, Or Signaling Without Affecting
- Gene Expression Profiling of Erbb Receptor and Ligand-Dependent
- Antibody Targeting of Eph Receptors in Cancer
- Molecular Mechanisms of Cardiotoxicity Induced by Erbb Receptor Inhibitor Cancer Therapeutics
- Erbb Receptors: from Oncogenes to Targeted Cancer Therapies
- Co-Expression of Cox-2, C-Met and Β-Catenin in Cells Forming Invasive Front of Gallbladder Cancer
- Combinatorial Targeting of FGF and Erbb Receptors Blocks Growth and Metastatic Spread of Breast Cancer Models Issa Et Al
- ERBB4 Promotes the Progression of Inflammatory Breast Cancer Through Regulating PDGFRA
- Epidermal Growth Factor Receptor Cytoplasmic Domain Mutations Trigger Ligand-Independent Transformation SHARON MASSOGLIA,' ALANE GRAY,' THOMAS J
- Activation of the EGFR Gene Target Epha2 Inhibits Epidermal Growth Factor–Induced Cancer Cell Motility
- Single Missense Mutation in the Tyrosine Kinase Catalytic Domain Of
- Bidirectional Signaling of Erbb and Eph Receptors at Synapses
- Antibody Targeting of Eph Receptors in Cancer
- Prospect for Anti-HER2 Receptor Therapy in Breast Cancer
- The Case for TRKB
- Expression Profiles of Erbb Family Receptors and Prognosis in Primary Transitional Cell Carcinoma of the Urinary Bladder1
- The Erbb3 Receptor Tyrosine Kinase Negatively Regulates Paneth Cells by PI3K-Dependent Suppression of Atoh1
- The Receptor Tyrosine Kinase Erbb3 Maintains the Balance Between Luminal and Basal Breast Epithelium
- Clinical and Prognostic Significances of Nuclear and Cytoplasmic KIT Expressions in Extrahepatic Bile Duct Carcinomas
- Tyrosine Kinase Receptor-Activated Signal Transduction Pathways Which Lead to Oncogenesis
- The Role of EGFR, Hepatocyte Growth Factor Receptor (C-Met), C-Erbb2 (HER2-Neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma
- Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers Or Dimers
- HER2/Neu Overexpression and Gene Amplification by Organ, Tumor Site and Histology
- Blocking C-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer